Bright Minds Biosciences (DRUG) Short-term Investments (2021 - 2026)

Bright Minds Biosciences has reported Short-term Investments for 6 years, with the latest figure at $125788.0 in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 109.27% year-over-year to $125788.0; the trailing twelve-month figure through Mar 2026 stood at $125788.0 (up 109.27% YoY), and the FY2025 full-year result was $62672.3, down 0.88% from the prior year.
• Short-term Investments for Q1 2026 stood at $125788.0, up from $123697.4 in the prior quarter.
• The five-year high for Short-term Investments was $125788.0 in Q1 2026, with the low at $60109.0 in Q1 2025.
• Historically, Short-term Investments has averaged $71465.8 across 5 years, with a median of $63669.7 in 2022.
• Annual changes were most pronounced in 2022 — Short-term Investments decreased 7.14% — and 2026, when it jumped 109.27%.
• Bright Minds Biosciences' Short-term Investments stood at $63540.6 in 2022, then fell by 0.29% to $63353.7 in 2023, then slipped by 2.54% to $61742.0 in 2024, then jumped by 100.35% to $123697.4 in 2025, then climbed by 1.69% to $125788.0 in 2026.
• The last three Short-term Investments figures came in at $125788.0 (Q1 2026), $123697.4 (Q4 2025), and $62672.3 (Q3 2025), per Business Quant data.